Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colorectal Neoplasms 96Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 44Prostatic Neoplasms 41Colonic Neoplasms 41Leukemia, Myeloid, Acute 40Nasopharyngeal Carcinoma 39Lymphoma, Large B-Cell, Diffuse 39Uterine Cervical Neoplasms 37Esophageal Neoplasms 33Ovarian Neoplasms 32Neoplasm Metastasis 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 23Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 18Squamous Cell Carcinoma of Head and Neck 17

Interventions

QL1206 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Bone Metastases × Clear all
NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
700 enrolled

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡